Recently, we reported that elevated longitudinal trajectories of tumor fractions, as detected by the untargeted modified Fast Aneuploidy Screening Test‐Sequencing System (mFAST‐SeqS), were significantly associated with a higher progression risk in patients with HR‐positive/HER2‐negative mBC. This evidence concerns the gene ERBB2 and neoplasm.